Breast cancer is the most common women's malignancy in the United States and is the
second leading cause of cancer death. More than half of patients with breast cancer
will develop hepatic metastases; this portends a poorer prognosis. In the appropriately
selected patient, there does appear to be a role for curative (surgery, ablation)
or palliative (intra-arterial treatments) locoregional therapy. Gynecologic malignancies
are less common and metastases to the liver are most often seen in the setting of
disseminated disease. The role of locoregional therapies in these patients is not
well reported. The purpose of this article is to review the outcomes data of locoregional
therapies in the treatment of hepatic metastases from breast and gynecologic malignancies.
Keywords
breast cancer - gynecologic malignancies - liver metastases - chemoembolization -
radioembolization - interventional radiology
